Europe
Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
The trial is the third study in a set of pivotal trials to report positive data for the therapy.
She takes over the role held by oncology research legend José Baselga, who passed away in March from a neurodegenerative disease.
Polyphor said there has been no improvement in the results for FORTRESS, its Phase III global study for the possible treatment of patients with breast cancer.
Multiple pharma company stocks make their first appearance on the Nasdaq this morning to advance the next-generation therapeutics. BioSpace takes a look at some of these IPOs.
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
A new class of compounds currently in development against acute myeloid leukemia has been discovered to block coronavirus reproduction in human lung cells.
German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management.
The analysis showed that the Pfizer and Oxford/AstraZeneca vaccines can protect patients from being hospitalized by as much as 90 percent.
PRESS RELEASES